BLA 761498 · Celltrion INC
Avtozma
Tocilizumab-Anoh · Iv (Infusion), Subcutaneous · Interleukin-6 Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jan 21, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
497
158 Phase 3, 67 recruiting
FAERS reports
31,077
29,569 serious, 6,639 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS INFECTIONS Patients treated with tocilizumab products including AVTOZMA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients, except those with COVID-19, should be tested for latent tuberculosis before AVTOZMA use and during therapy. Treatment for latent infection should be initiated prior to AVTOZMA use. Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal...
What it is approved for
From the label in effect Oct 20, 2026.
AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.4 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.5 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.6 ) Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of giant cell arteritis (GCA) in adult patients. 1.3 Polyarticular Juvenile Idiopathic Arthritis (PJIA) AVTOZMA ® (tocilizumab-anoh) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age...
Mechanism: Tocilizumab products bind to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation....
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 21, 2026 Original approval LabelMedication GuideLetter
4 products under this application
- AVTOZMA · TOCILIZUMAB-ANOH 400MG/20ML(20MG/ML) · INJECTABLE, IV (INFUSION) · Prescription
- AVTOZMA · TOCILIZUMAB-ANOH 80MG/4ML(20MG/ML) · INJECTABLE, IV (INFUSION) · Prescription
- AVTOZMA · TOCILIZUMAB-ANOH 162MG/20ML(20MG/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- AVTOZMA · TOCILIZUMAB-ANOH 200MG/10ML(20MG/ML) · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tocilizumab" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk FactorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01331837 · 3,080 participants · Start Aug 2, 2011 · Primary completion Mar 25, 2016
Drug: Etanercept; Tocilizumab · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 428 sites in all
- An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00720798 · 2,067 participants · Start Sep 2005 · Primary completion Apr 2013
Drug: Tocilizumab; Disease-modifying anti-rheumatic drugs and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 295 sites in all
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06381661 · 2,000 participants (planned) · Start Jul 9, 2026 · Primary completion Aug 9, 2028
Drug: Tocilizumab; Baricitinib and 13 more · For: Sepsis
Sites: Dijon, France; Étampes, France; Garches, France · 19 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00750880 · 1,681 participants · Start Sep 2008 · Primary completion Jul 2011
Drug: tocilizumab [RoActemra/Actemra] · For: Rheumatoid Arthritis
Sites: Canberra, Australia; Coffs Harbour, Australia; Kogarah, Australia · 282 sites in all
- A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid ArthritisPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01194414 · 1,262 participants · Start Sep 2010 · Primary completion Jan 2012
Drug: tocilizumab SC; tocilizumab IV and 3 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Tuscaloosa, Alabama; Tucson, Arizona · 216 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use9,470
- drug ineffective7,205
- rheumatoid arthritis5,114
- pain4,587
- fatigue3,999
- rash3,917
- contraindicated product administered3,630
- drug intolerance3,389
- arthropathy3,343
- product use issue3,271
- alopecia3,265
- arthralgia3,264
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 11 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 520 |
| 2011 | 424 |
| 2012 | 512 |
| 2013 | 663 |
| 2014 | 449 |
| 2015 | 474 |
| 2016 | 617 |
| 2017 | 751 |
| 2018 | 1,218 |
| 2019 | 1,328 |
| 2020 | 3,306 |
| 2021 | 4,517 |
| 2022 | 4,692 |
| 2023 | 3,475 |
| 2024 | 3,510 |
| 2025 | 2,774 |
| 2026 | 1,820 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Celltrion INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.